Year-over-year earnings per share growth for the last twelve months: journeymedicalcorp.com (DERM)

Journey Medical Corp. - graphic logo of issuer DERM

The investment attractiveness of Journey Medical (DERM) is based on its in-house production of dermatological products and established distribution channels. The quarterly earnings per share (EPS) growth trend on the GURU.Markets chart confirms this, where 49.10 represents the latest metric reading. Growth is driven by the scaling of Emrosi sales, while independence from macroeconomic factors makes the asset a defensive tool during market downturns.

Journey Medical Corporation (DERM) Year-over-year earnings per share growth rate for the last twelve months: for the period 07/04/2022 - 11/17/2026

DERM (Journey Medical Corporation): analytical breakdowns and indicator data

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Summary company analytics:Journey Medical
Finished products of journeymedicalcorp.com

The fundamental resilience of the business is determined by its ability to generate net income per share. This indicator captures the percentage change in profit per quarter, reflecting the efficiency of cost management. For Journey Medical (DERM), this is a critical marker of the transition to profitability while scaling sales of the rosacea drug. B2B distribution dynamics directly impact the bottom line. By analyzing this quarterly EPS chart, an investor can see the actual pace of commercial expansion.

Key competitors

KRYS: Quarterly EPS earnings growth|APGE - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Arcutis Biotherapeutics, Inc.|Year-over-year earnings per share growth for the last 12 months VCEL (Vericel)|Year-over-year earnings per share growth for the last twelve months Oruka Pharma (ORKA)|Year-over-year net earnings per share change for the last twelve months Sanara MedTech|Quarterly EPS earnings growth DBVT (DBV Technologies SA)|Solesence Inc (SLSN) - Earnings per share growth in annualized terms for the last twelve months|FBRX - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months EMPG|SLGL (sol-gel.com) - Year-over-year net earnings per share growth for the last 12 months|AXIL (AXIL Brands, Inc.) - Year-over-year earnings per share growth for the last twelve months|MDCX (Medicus Pharma Corp) - Quarterly EPS earnings growth|Verrica Pharmaceuticals (VRCA) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HOTH (Hoth Therapeutics, Inc.)|BFRI - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth VYNE (VYNE Therapeutics)|Year-over-year earnings per one share growth for the last 12 months SNOA|Quoin Pharmaceuticals Ltd. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Azitra Corporation AZTR|DRMA (Dermata) - Year-over-year net earnings per share growth for the last 12 months|Elevai Labs Inc. (ELAB) - Quarterly EPS earnings growth|RVNC (Revance Therapeutics, Inc.) - Quarterly EPS earnings growth